




NATIONAL INSTITUTE FOR  
COMMUNICABLE DISEASES

Division of the National Health Laboratory Service

# Notifiable Medical Conditions Surveillance System Report



May 2026

Division of Public Health, Surveillance and Response

## Introduction

This report summarises data from the Notifiable Medical Conditions Surveillance System (NMCSS) for cases notified during May (**ISO Weeks 18–22**). It includes Category 1, 2, and 3 notifiable medical conditions (NMCs). The report presents the distribution of case notifications by notification source (clinical, laboratory, and merged cases; **Table 1**), epidemiological classification, demographics, and reported deaths. In addition, it assesses key NMCSS data quality indicators, including the completeness and timeliness of notifications following diagnosis, as well as delayed (back-captured) cases notified.

## NMC highlights

- A total of 12 446 cases were notified to the NMCSS in May, and 1 033 were back captured (**Appendix A**).
- At least 18.5% of category 1 notifications were successfully linked by matching clinical notifications to their corresponding laboratory results.
- Majority of the category 1 notifications were measles (n=951, 42.9%) and malaria (n=796, 35.9%).
- A total of 110 cases of agricultural stock or remedy poisoning were notified, of which 11 (10.0%) were reported as deaths.
- Overall, it took a median of less than a day (**IQR: 0-1 day**) to report category 1 NMCs.

**Table 1.** NMC notifications by category and case type, May 2026

| Categories          | Clinical             | Laboratory           | Merged            | Total, n (%)  |
|---------------------|----------------------|----------------------|-------------------|---------------|
| 1                   | 1 240 (14.3%)        | 565 (26.2%)          | 410 (66.6%)       | 2 215 (19.4%) |
| 2                   | 7 402 (85.7%)        | 1 464 (67.9%)        | 201 (32.6%)       | 9 067 (79.4%) |
| 3                   | 0 (0.0%)             | 126 (5.8%)           | 5 (0.8%)          | 131 (1.1%)    |
| <b>Total, n (%)</b> | <b>8 642 (75.7%)</b> | <b>2 155 (18.9%)</b> | <b>616 (5.4%)</b> | <b>11 413</b> |

## NMC Category 1 conditions

A total of 2 215 (19.4%) category 1 cases were reported (**Tables 1 and 2**). The majority were measles (n=951, 42.8%). The weekly [measles and rubella situational reports](#) and [measles/rubella dashboards](#) provide detailed epidemiological analysis. Further epidemiological classification of diphtheria is underway, and the [weekly situational report](#) provides detailed epidemiological analysis. Two cases of [Hantavirus pulmonary syndrome \(HPS\)](#) linked to the MV Hondius cruise ship were tested and laboratory confirmed in Gauteng (NICD Lab). Additional information is available in the [NICD Pulse](#). Two confirmed Mpox cases were reported in the Western Cape. The majority (n=46, 41.8%) of the agricultural or stock remedy poisoning (ASRP) cases were reported in Gauteng (**Table 2**). Furthermore, 10% (n=11) of ASRP cases were reported as deaths (**Table 3**).

**Table 2.** Category 1 NMC notifications by province, May 2026

| Condition                                                          | EC                | FS                 | GP                 | KZN               | LP                 | MP                 | NC               | NW               | WC                 | Total, n (%) |
|--------------------------------------------------------------------|-------------------|--------------------|--------------------|-------------------|--------------------|--------------------|------------------|------------------|--------------------|--------------|
| Acute Flaccid Paralysis                                            | 4 (13.3%)         | 0 (0.0%)           | 4 (13.3%)          | 1 (3.3%)          | 8 (26.7%)          | 1 (3.3%)           | 3 (10.0%)        | 3 (10.0%)        | 6 (20.0%)          | 30 (1.4%)    |
| Acute Rheumatic Fever                                              | 0 (0.0%)          | 0 (0.0%)           | 1 (33.3%)          | 1 (33.3%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 1 (33.3%)          | 3 (0.1%)     |
| Agricultural or stock remedy poisoning                             | 5 (4.5%)          | 15 (13.6%)         | 46 (41.8%)         | 6 (5.5%)          | 11 (10.0%)         | 7 (6.4%)           | 2 (1.8%)         | 8 (7.3%)         | 10 (9.1%)          | 110 (5.0%)   |
| Botulism                                                           | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 1 (100.0%)       | 0 (0.0%)         | 0 (0.0%)           | 1 (0.0%)     |
| Congenital rubella syndrome                                        | 0 (0.0%)          | 0 (0.0%)           | 1 (33.3%)          | 0 (0.0%)          | 0 (0.0%)           | 1 (33.3%)          | 0 (0.0%)         | 0 (0.0%)         | 1 (33.3%)          | 3 (0.1%)     |
| Diphtheria                                                         | 0 (0.0%)          | 0 (0.0%)           | 1 (5.6%)           | 1 (5.6%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 16 (88.9%)         | 18 (0.8%)    |
| Enteric fever (typhoid or paratyphoid fever)                       | 0 (0.0%)          | 0 (0.0%)           | 6 (42.9%)          | 1 (7.1%)          | 1 (7.1%)           | 4 (28.6%)          | 0 (0.0%)         | 0 (0.0%)         | 2 (14.3%)          | 14 (0.6%)    |
| Food borne illness outbreak                                        | 1 (4.5%)          | 3 (13.6%)          | 8 (36.4%)          | 5 (22.7%)         | 2 (9.1%)           | 3 (13.6%)          | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 22 (1.0%)    |
| Listeriosis                                                        | 0 (0.0%)          | 0 (0.0%)           | 2 (40.0%)          | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 3 (60.0%)          | 5 (0.2%)     |
| Malaria*                                                           | 10 (1.3%)         | 13 (1.6%)          | 116 (14.6%)        | 103 (12.9%)       | 273 (34.3%)        | 236 (29.6%)        | 6 (0.8%)         | 19 (2.4%)        | 20 (2.5%)          | 796 (35.9%)  |
| Measles                                                            | 82 (8.6%)         | 188 (19.8%)        | 100 (10.5%)        | 22 (2.3%)         | 95 (10.0%)         | 65 (6.8%)          | 79 (8.3%)        | 33 (3.5%)        | 287 (30.2%)        | 951 (42.9%)  |
| Meningococcal Disease                                              | 1 (5.3%)          | 0 (0.0%)           | 5 (26.3%)          | 2 (10.5%)         | 0 (0.0%)           | 2 (10.5%)          | 0 (0.0%)         | 1 (5.3%)         | 8 (42.1%)          | 19 (0.9%)    |
| Mercury poisoning                                                  | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)          | 0 (0.0%)           | 1 (100.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.0%)     |
| Mpox                                                               | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 2 (100.0%)         | 2 (0.1%)     |
| Pertussis                                                          | 7 (4.0%)          | 14 (8.0%)          | 81 (46.3%)         | 24 (13.7%)        | 13 (7.4%)          | 3 (1.7%)           | 1 (0.6%)         | 10 (5.7%)        | 22 (12.6%)         | 175 (7.9%)   |
| Poliomyelitis                                                      | 1 (100.0%)        | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.0%)     |
| Respiratory disease caused by a novel Respiratory pathogen – HPS** | 0 (0.0%)          | 0 (0.0%)           | 2 (100.0%)         | 0 (0.0%)          | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 2 (0.1%)     |
| Rubella                                                            | 5 (8.1%)          | 13 (21.0%)         | 11 (17.7%)         | 3 (4.8%)          | 5 (8.1%)           | 3 (4.8%)           | 6 (9.7%)         | 3 (4.8%)         | 13 (21.0%)         | 62 (2.8%)    |
| <b>Total, n (%)</b>                                                | <b>116 (5.2%)</b> | <b>246 (11.1%)</b> | <b>384 (17.3%)</b> | <b>169 (7.6%)</b> | <b>408 (18.4%)</b> | <b>326 (14.7%)</b> | <b>98 (4.4%)</b> | <b>77 (3.5%)</b> | <b>391 (17.7%)</b> | <b>2 215</b> |

\*Malaria diagnosis method: Rapid test (n= 402), Laboratory confirmed (n=394). \*\*Hantavirus pulmonary syndrome confirmed cases.


**Table 3:** Category 1 NMC notifications by epidemiological classification and patient vital status, May 2026

| Condition                                                          | Clinical notification | Laboratory notification | Epidemiological classification |                      |                  |                  | Patient vital status |                   |                    | Total, n(%)  |
|--------------------------------------------------------------------|-----------------------|-------------------------|--------------------------------|----------------------|------------------|------------------|----------------------|-------------------|--------------------|--------------|
|                                                                    |                       |                         | Confirmed case                 | Asymptomatic carrier | Probable case    | Suspected case   | Alive                | Deceased          | Unknown            |              |
| Acute Flaccid Paralysis                                            | 30 (100.0%)           | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 29 (96.7%)           | 1 (3.3%)          | 0 (0.0%)           | 30 (1.4%)    |
| Acute Rheumatic Fever                                              | 0 (0.0%)              | 0 (0.0%)                | 1 (33.3%)                      | 0 (0.0%)             | 1 (33.3%)        | 1 (33.3%)        | 3 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 3 (0.1%)     |
| Agricultural or stock remedy poisoning                             | 110 (100.0%)          | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 99 (90.0%)           | 11 (10.0%)        | 0 (0.0%)           | 110 (5.0%)   |
| Botulism                                                           | 1 (100.0%)            | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 1 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 1 (0.0%)     |
| Congenital rubella syndrome                                        | 2 (66.7%)             | 1 (33.3%)               | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 3 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 3 (0.1%)     |
| Diphtheria                                                         | 0 (0.0%)              | 0 (0.0%)                | 8 (44.4%)                      | 2 (11.1%)            | 0 (0.0%)         | 8 (44.4%)        | 15 (83.3%)           | 0 (0.0%)          | 3 (16.7%)          | 18 (0.8%)    |
| Enteric fever (typhoid or paratyphoid fever)                       | 0 (0.0%)              | 0 (0.0%)                | 14 (100.0%)                    | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 7 (50.0%)            | 1 (7.1%)          | 6 (42.9%)          | 14 (0.6%)    |
| Food borne illness outbreak                                        | 22 (100.0%)           | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 22 (100.0%)          | 0 (0.0%)          | 0 (0.0%)           | 22 (1.0%)    |
| Listeriosis                                                        | 1 (20.0%)             | 0 (0.0%)                | 4 (80.0%)                      | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 5 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 5 (0.2%)     |
| Malaria*                                                           | 513 (64.4%)           | 226 (28.4%)             | 57 (7.2%)                      | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 627 (78.8%)          | 7 (0.9%)          | 162 (20.4%)        | 796 (35.9%)  |
| Measles                                                            | 443 (46.6%)           | 374 (39.3%)             | 134 (14.1%)                    | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 506 (53.2%)          | 0 (0.0%)          | 445 (46.8%)        | 951 (42.9%)  |
| Meningococcal Disease                                              | 0 (0.0%)              | 0 (0.0%)                | 12 (63.2%)                     | 0 (0.0%)             | 0 (0.0%)         | 7 (36.8%)        | 13 (68.4%)           | 6 (31.6%)         | 0 (0.0%)           | 19 (0.9%)    |
| Mercury poisoning                                                  | 1 (100.0%)            | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 1 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 1 (0.0%)     |
| Mpox                                                               | 0 (0.0%)              | 0 (0.0%)                | 2 (100.0%)                     | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 2 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 2 (0.1%)     |
| Pertussis                                                          | 0 (0.0%)              | 0 (0.0%)                | 133 (76.0%)                    | 0 (0.0%)             | 13 (7.4%)        | 29 (16.6%)       | 153 (87.4%)          | 0 (0.0%)          | 22 (12.6%)         | 175 (7.9%)   |
| Poliomyelitis                                                      | 1 (100.0%)            | 0 (0.0%)                | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 1 (100.0%)           | 0 (0.0%)          | 0 (0.0%)           | 1 (0.0%)     |
| Respiratory disease caused by a novel respiratory pathogen – HPS** | 0 (0.0%)              | 0 (0.0%)                | 2 (100.0%)                     | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 1 (50.0%)            | 1 (50.0%)         | 0 (0.0%)           | 2 (0.1%)     |
| Rubella                                                            | 11 (17.7%)            | 51 (82.3%)              | 0 (0.0%)                       | 0 (0.0%)             | 0 (0.0%)         | 0 (0.0%)         | 14 (22.6%)           | 0 (0.0%)          | 48 (77.4%)         | 62 (2.8%)    |
| <b>Total, n (%)</b>                                                | <b>1 135 (0.1%)</b>   | <b>652 (0.1%)</b>       | <b>367 (0.1%)</b>              | <b>2 (0.1%)</b>      | <b>14 (0.1%)</b> | <b>45 (0.1%)</b> | <b>1 502 (67.8%)</b> | <b>27 (67.8%)</b> | <b>686 (67.8%)</b> | <b>2 215</b> |

\*Malaria diagnosis method: Rapid test (n= 402), Laboratory confirmed (n=394). \*\* Hantavirus pulmonary syndrome confirmed cases.

### Distribution of Category 1 NMC notifications by age and sex, May 2026

Majority of the category 1 NMC notifications were male (n=1 302, 58.6%) and individuals in the 0-9 age group (n=909, 40.9%; **Figures 1 and 2**). Male patients were mostly affected by measles (n=514, 54.0%) with a median age of seven years, and malaria (n=555, 69.7%) with a median age of 26 years.



**Figure 1.** Distribution of Category 1 NMC notifications by age groups and sex, May 2026.





Figure 2. Category 1 NMC notifications by condition and age groups, May 2026

### NMC Category 1 hospital form completion

At least 852 (38.5%) category 1 NMC cases with reported admission status as inpatients (n=601, 70.5%), discharged (n=166, 19.5%), or transferred out (n=85, 10.0%), making these cases eligible for completion of the hospitalisation form. For either admission status (**Figure 3**), the majority had the hospitalisation form incomplete (n=684, 80.2%).



**Figure 3.** Completion of the hospitalisation form for Category 1 NMC notifications, May 2026

## NMC Category 2 Notifications

The commonly notified category 2 conditions in May 2026 were pulmonary TB (n=5 680, 62.6%) and extra-pulmonary TB (n=1 281, 14.1%; [Table 4](#)). The [End TB dashboard](#) provides detailed epidemiology of TB in South Africa. Two cases of leprosy were reported in the Eastern Cape.


**Table 4:** Category 2 notifications by province, May 2026

| Condition                                             | EC                | FS                | GP                   | KZN                  | LP                | MP                | NC                | NW                | WC                   | Total, n (%)  |
|-------------------------------------------------------|-------------------|-------------------|----------------------|----------------------|-------------------|-------------------|-------------------|-------------------|----------------------|---------------|
| Bilharzia (schistosomiasis)                           | 51 (6.2%)         | 0 (0.0%)          | 40 (2.1%)            | 409 (15.4%)          | 197 (28.6%)       | 118 (31.3%)       | 0 (0.0%)          | 3 (0.7%)          | 21 (1.5%)            | 839 (9.3%)    |
| Brucellosis                                           | 1 (0.1%)          | 0 (0.0%)          | 0 (0.0%)             | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 1 (0.0%)      |
| Congenital syphilis                                   | 3 (0.4%)          | 1 (0.3%)          | 19 (1.0%)            | 45 (1.7%)            | 2 (0.3%)          | 3 (0.8%)          | 3 (0.7%)          | 3 (0.7%)          | 42 (3.1%)            | 121 (1.3%)    |
| Haemophilus influenzae type B                         | 0 (0.0%)          | 0 (0.0%)          | 1 (0.1%)             | 0 (0.0%)             | 1 (0.1%)          | 0 (0.0%)          | 1 (0.2%)          | 1 (0.2%)          | 0 (0.0%)             | 4 (0.0%)      |
| Hepatitis A                                           | 13 (1.6%)         | 12 (3.0%)         | 34 (1.8%)            | 17 (0.6%)            | 19 (2.8%)         | 14 (3.7%)         | 6 (1.5%)          | 19 (4.3%)         | 47 (3.5%)            | 181 (2.0%)    |
| Hepatitis B                                           | 105 (12.8%)       | 19 (4.8%)         | 65 (3.4%)            | 503 (18.9%)          | 14 (2.0%)         | 7 (1.9%)          | 26 (6.4%)         | 24 (5.4%)         | 15 (1.1%)            | 778 (8.6%)    |
| Hepatitis C                                           | 1 (0.1%)          | 1 (0.3%)          | 7 (0.4%)             | 1 (0.0%)             | 1 (0.1%)          | 0 (0.0%)          | 0 (0.0%)          | 1 (0.2%)          | 1 (0.1%)             | 13 (0.1%)     |
| Hepatitis E                                           | 1 (0.1%)          | 0 (0.0%)          | 0 (0.0%)             | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 1 (0.0%)      |
| Lead poisoning                                        | 0 (0.0%)          | 1 (0.3%)          | 0 (0.0%)             | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 1 (0.0%)      |
| Legionellosis                                         | 3 (0.4%)          | 1 (0.3%)          | 6 (0.3%)             | 0 (0.0%)             | 0 (0.0%)          | 1 (0.3%)          | 0 (0.0%)          | 1 (0.2%)          | 7 (0.5%)             | 19 (0.2%)     |
| Leprosy                                               | 2 (0.2%)          | 0 (0.0%)          | 0 (0.0%)             | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 2 (0.0%)      |
| Maternal death (pregnancy, childbirth and puerperium) | 1 (0.1%)          | 0 (0.0%)          | 1 (0.1%)             | 0 (0.0%)             | 1 (0.1%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 3 (0.0%)      |
| Soil transmitted helminths                            | 0 (0.0%)          | 0 (0.0%)          | 1 (0.1%)             | 0 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 1 (0.0%)      |
| Tetanus                                               | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 0 (0.0%)             | 1 (0.1%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)          | 0 (0.0%)             | 1 (0.0%)      |
| Tuberculosis: extensively drug - resistant (XDR -TB)  | 0 (0.0%)          | 0 (0.0%)          | 2 (0.1%)             | 1 (0.0%)             | 0 (0.0%)          | 0 (0.0%)          | 1 (0.2%)          | 0 (0.0%)          | 2 (0.1%)             | 6 (0.1%)      |
| Tuberculosis: multidrug- resistant (MDR -TB)          | 12 (1.5%)         | 15 (3.8%)         | 36 (1.9%)            | 24 (0.9%)            | 9 (1.3%)          | 1 (0.3%)          | 3 (0.7%)          | 2 (0.4%)          | 33 (2.4%)            | 135 (1.5%)    |
| Tuberculosis: extra-pulmonary                         | 95 (11.6%)        | 62 (15.5%)        | 471 (24.6%)          | 300 (11.3%)          | 57 (8.3%)         | 36 (9.5%)         | 48 (11.8%)        | 60 (13.4%)        | 152 (11.2%)          | 1 281 (14.1%) |
| Tuberculosis: pulmonary                               | 530 (64.8%)       | 287 (71.9%)       | 1 234 (64.4%)        | 1 356 (51.1%)        | 388 (56.2%)       | 197 (52.3%)       | 320 (78.4%)       | 333 (74.5%)       | 1 035 (76.4%)        | 5 680 (62.6%) |
| <b>Total, n (%)</b>                                   | <b>818 (9.0%)</b> | <b>399 (4.4%)</b> | <b>1 917 (21.1%)</b> | <b>2 656 (29.3%)</b> | <b>690 (7.6%)</b> | <b>377 (4.2%)</b> | <b>408 (4.5%)</b> | <b>447 (4.9%)</b> | <b>1 355 (14.9%)</b> | <b>9 067</b>  |



### Distribution of Category 2 NMC notifications by age and sex, May 2026

Majority of the category 2 NMC notifications were male (n=5 265, 58.1%) and individuals in the 30 to 49 age group (n= 3 124, 34.5%; **Figure 4**). Male patients were mostly affected by pulmonary tuberculosis.



**Figure 4.** Distribution of NMC Category 2 by age and sex, May 2026

### NMC Category 3 conditions

The Western Cape reported the most (n=80, 61.1%) of the category 3 conditions (**Table 5**). Limpopo and Mpumalanga provinces had no category 3 conditions diagnosed.

**Table 5:** Distribution of category 3 notification by province, May 2026

| Condition                   | GP                | EC                | FS              | KZN             | LP              | MP              | NC              | NW              | WC                | Total, n (%) |
|-----------------------------|-------------------|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-------------------|--------------|
| Dengue Fever Virus          | 1 (5.9%)          | 0 (0.0%)          | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)          | 1 (0.8%)     |
| Non-typhoidal Salmonellosis | 12 (70.6%)        | 10 (50.0%)        | 1 (50.0%)       | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 0 (0.0%)        | 46 (57.5%)        | 69 (52.7%)   |
| Shigellosis                 | 4 (23.5%)         | 10 (50.0%)        | 1 (50.0%)       | 7 (100.0%)      | 0 (0.0%)        | 0 (0.0%)        | 4 (100.0%)      | 1 (100.0%)      | 34 (42.5%)        | 61 (46.6%)   |
| <b>Total, n (%)</b>         | <b>17 (13.0%)</b> | <b>20 (15.3%)</b> | <b>2 (1.5%)</b> | <b>7 (5.3%)</b> | <b>0 (0.0%)</b> | <b>0 (0.0%)</b> | <b>4 (3.1%)</b> | <b>1 (0.8%)</b> | <b>80 (61.1%)</b> | <b>131</b>   |

### Timeliness and completeness of NMC data

Timeliness is measured as the number of days from the time of diagnosis of the NMC to the time of notification. This analysis excludes cases where date of diagnosis was missing. Overall, it took a median of less than a day (**IQR: 0- 1 day**) to report category 1 NMCs in May 2026 (**Table 6**).

**Table 6:** Time to notification of category 1 and 2 NMC, May 2026

|                   |                      | EC      | FS      | GP      | KZN     | LP      | MP         | NC      | NW      | WC      | Overall |
|-------------------|----------------------|---------|---------|---------|---------|---------|------------|---------|---------|---------|---------|
| <b>Category 1</b> | n                    | 116     | 246     | 384     | 169     | 408     | 326        | 98      | 77      | 391     | 2215    |
|                   | <b>Median (IQR*)</b> | 0 (0–1) | 0 (0–1) | 1 (0–2) | 0 (0–0) | 0 (0–0) | 0 (0–0)    | 0 (0–1) | 0 (0–2) | 0 (0–0) | 0 (0–1) |
| <b>Category 2</b> | n                    | 818     | 399     | 1917    | 2656    | 690     | 377        | 408     | 447     | 1355    | 9067    |
|                   | <b>Median (IQR*)</b> | 2 (0–7) | 2 (0–7) | 2 (0–7) | 2 (0–6) | 1 (0–5) | 1 (0–6.25) | 3 (0–8) | 1 (0–6) | 1 (0–6) | 2 (0–7) |

\*IQR: Interquartile range

Completeness refers to the proportion of complete data entries per variable in the dataset among clinical and merged notifications. **Figure 4** reports a completion rate of more than 80% for patient address and 62.5% for national identification number.




Figure 5. Data completeness of key patient identification variables, May 2026.

## Recommendations

- We recommend that clinicians complete all patient clinical and demographic details to improve NMC data quality.
- We recommend completion of the hospitalisation form for all patients admitted to the hospital with category 1 NMCs.
- Feel free to reach out to [NMCsurveillanceReport@nicd.ac.za](mailto:NMCsurveillanceReport@nicd.ac.za)

**Appendix A: Back-captured notifications:** all cases diagnosed in previous months and before the last 11 days of April 2026 and notified during May 2026.

| Condition                                          | EC               | FS                 | GP                 | KZN                | LP               | MP               | NC               | NW               | WC                 | Total        |
|----------------------------------------------------|------------------|--------------------|--------------------|--------------------|------------------|------------------|------------------|------------------|--------------------|--------------|
| Agricultural or stock remedy poisoning             | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 2 (40.0%)        | 0 (0.0%)         | 3 (60.0%)        | 0 (0.0%)           | 5 (0.5%)     |
| Bilharzia (schistosomiasis)                        | 0 (0.0%)         | 0 (0.0%)           | 1 (20.0%)          | 0 (0.0%)           | 4 (80.0%)        | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 5 (0.5%)     |
| Congenital syphilis                                | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 11 (100.0%)        | 11 (1.1%)    |
| Hepatitis A                                        | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 1 (50.0%)          | 0 (0.0%)         | 0 (0.0%)         | 1 (50.0%)        | 0 (0.0%)         | 0 (0.0%)           | 2 (0.2%)     |
| Hepatitis B                                        | 3 (11.5%)        | 2 (7.7%)           | 13 (50.0%)         | 6 (23.1%)          | 1 (3.8%)         | 1 (3.8%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 26 (2.5%)    |
| Hepatitis C                                        | 0 (0.0%)         | 0 (0.0%)           | 5 (100.0%)         | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 5 (0.5%)     |
| Legionellosis                                      | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 1 (100.0%)       | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.1%)     |
| Leprosy                                            | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 1 (100.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.1%)     |
| Malaria                                            | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 1 (50.0%)        | 0 (0.0%)         | 0 (0.0%)         | 1 (50.0%)          | 2 (0.2%)     |
| Measles                                            | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)           | 0 (0.0%)         | 1 (100.0%)       | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.1%)     |
| Pertussis                                          | 0 (0.0%)         | 0 (0.0%)           | 0 (0.0%)           | 1 (100.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)         | 0 (0.0%)           | 1 (0.1%)     |
| Tuberculosis: extensively drug-resistant (XDR -TB) | 0 (0.0%)         | 0 (0.0%)           | 1 (33.3%)          | 0 (0.0%)           | 0 (0.0%)         | 0 (0.0%)         | 1 (33.3%)        | 1 (33.3%)        | 0 (0.0%)           | 3 (0.3%)     |
| Tuberculosis: multidrug-resistant (MDR -TB)        | 1 (3.8%)         | 1 (3.8%)           | 7 (26.9%)          | 9 (34.6%)          | 4 (15.4%)        | 0 (0.0%)         | 0 (0.0%)         | 1 (3.8%)         | 3 (11.5%)          | 26 (2.5%)    |
| Tuberculosis: extra-pulmonary                      | 10 (5.9%)        | 18 (10.7%)         | 51 (30.2%)         | 32 (18.9%)         | 4 (2.4%)         | 3 (1.8%)         | 8 (4.7%)         | 3 (1.8%)         | 40 (23.7%)         | 169 (16.4%)  |
| Tuberculosis: pulmonary                            | 70 (9.0%)        | 102 (13.2%)        | 199 (25.7%)        | 142 (18.3%)        | 18 (2.3%)        | 20 (2.6%)        | 74 (9.5%)        | 13 (1.7%)        | 137 (17.7%)        | 775 (75.0%)  |
| <b>Total, n (%)</b>                                | <b>84 (8.1%)</b> | <b>123 (11.9%)</b> | <b>277 (26.8%)</b> | <b>192 (18.6%)</b> | <b>31 (3.0%)</b> | <b>29 (2.8%)</b> | <b>84 (8.1%)</b> | <b>21 (2.0%)</b> | <b>192 (18.6%)</b> | <b>1 033</b> |

## Additional resources

NMC reporting tutorials video: <https://www.nicd.ac.za/nmc-overview/tutorial-videos/>

NMC Categories, and Case Classification Definitions: <https://www.nicd.ac.za/nmc-overview/nmc-resources/>

## NMC Surveillance Officers List and contacts

| Province            | Name & Surname        | Email address                                                      | Cell Numbers              |
|---------------------|-----------------------|--------------------------------------------------------------------|---------------------------|
| Eastern Cape        | -                     | -                                                                  | 072 621 3805              |
| Free State          | Moeketsi Pheko        | <a href="mailto:moeketsip@nicd.ac.za">moeketsip@nicd.ac.za</a>     | 060 978 3043/076 889 7319 |
| Gauteng & Northwest | Bukelani Nyawose      | <a href="mailto:bukelanin@nicd.ac.za">bukelanin@nicd.ac.za</a>     | 071 670 8741              |
| KwaZulu-Natal       | Sharika Naidoo        | <a href="mailto:sharikan@nicd.ac.za">sharikan@nicd.ac.za</a>       | 071 303 7392              |
| Limpopo             | Vuyolwethu Mashamaite | <a href="mailto:vuyolwethum@nicd.ac.za">vuyolwethum@nicd.ac.za</a> | 060 963 4834              |
| Mpumalanga          | Lesley Ingle          | <a href="mailto:lesleyl@nicd.ac.za">lesleyl@nicd.ac.za</a>         | 066 308 7539              |
| Northern Cape       | Matsheko Thekiso      | <a href="mailto:matshekot@nicd.ac.za">matshekot@nicd.ac.za</a>     | 060 984 0908              |
| Western Cape        | Washiefa Isaacs       | <a href="mailto:washiefal@nicd.ac.za">washiefal@nicd.ac.za</a>     | 064 742 4005              |

**The End!**